Evotec SE

What they do

Evotec operates two primary segments: Shared R&D and Just Evotec Biologics. Shared R&D provides integrated drug discovery, development, and related services on a fee-for-service and milestone basis. Just Evotec Biologics focuses on biologics discovery, development, and manufacturing, including end-to-end services for antibody and protein therapeutics.

Revenue drivers

• Shared R&D — Generates revenue primarily from service fees and FTE-based research payments, milestones, and recharges. Revenue is recognized over time as services are performed.
• Just Evotec Biologics — Revenue derived from biologics development and manufacturing services, also recognized over time. This segment includes the J.POD manufacturing platform.
• Licenses (included in Shared R&D) — Revenue from licensing deals, recognized at point in time when milestones are achieved or licenses are delivered.

Recent performance

For fiscal year 2025, Evotec reported total revenue of €195.386 million (as per 20-F cover). The company's revenue mix shows significant contributions from US and European customers, with the US being the largest geographic market for Shared R&D and Just Evotec Biologics. Management noted continued growth in the biologics segment, though specific figures for 2025 vs 2024 were not fully extracted.

Strategy

Evotec's strategy centers on expanding its integrated drug discovery and development platform, with a focus on its Just Evotec Biologics segment and the J.POD technology. The company is investing in capacity and capabilities to serve large pharma and biotech customers, aiming to build long-term partnerships. It continues to emphasize milestone-based deals and licensing to drive value beyond fee-for-service work.

Risks

• Customer concentration — A major customer in Shared R&D and Just Evotec Biologics could cause revenue volatility if that relationship changes.
• Geographic risk — Significant revenue from the US and Germany (DE) exposes Evotec to regional economic and regulatory shifts.
• Development risk — Milestone and license revenue depend on successful achievement of development milestones, which may fail.
• Operational execution — Capacity expansion and J.POD platform scaling may face execution delays or cost overruns.

Outlook

Management indicates continued investment in the biologics segment and expansion of its service offerings. The company expects to benefit from growing demand for outsourced drug development and manufacturing. Forward-looking statements highlight planned capacity increases and potential new partnership agreements.